What is the common examiner trap about Science & Tech in UPSC exams?

Confusing PCSK9 inhibitors with statins: Statins reduce cholesterol production in the liver, while PCSK9 inhibitors help the liver clear existing LDL from blood. Also, mixing up Lipfendra with other lipid-lowering drugs like ezetimibe (gut absorption blocker) or bempedoic acid.

What should UPSC aspirants remember about Science & Tech for Prelims?

1. Target this Data: Lipfendra (enlicitide) reduces LDL by up to 60% and ApoB by ~50%. 2. Target this Nodal Body: US FDA approved the drug; developer is Merck. 3. Target this Mechanism: PCSK9 inhibitor – blocks PCSK9 protein to increase LDL receptors on liver.

Science_TechHealth

Take AI Challenge ▸

News 0 of 29

FDA Approves Lipfendra (Enlicitide) Oral PCSK9 Inhibitor, Slashes LDL by 60%

Q: Which regulatory body approved the new oral PCSK9 inhibitor Lipfendra (enlicitide)?

US Food and Drug Administration (FDA), The article clearly states that the US FDA approved the pill version called Lipfendra (enlicitide). The DCGI is India's drug regulator, EMA is European, and WHO does not approve drugs for market use.

Q: Consider the following statements regarding Lipfendra (enlicitide): 1. It is a PCSK9 inhibitor that reduces LDL cholesterol by up to 60%. 2. It works by reducing the liver's production of cholesterol, similar to statins. 3. It also reduces apolipoprotein B (ApoB) levels by about 50%. Which of the statements given above is/are correct?

Both 1 and 3, Statement 1 is correct as the article states Lipfendra is a PCSK9 inhibitor that brings LDL down by up to 60%. Statement 2 is incorrect because statins reduce cholesterol production, while PCSK9 inhibitors help the liver clear LDL from the bloodstream. Statement 3 is correct as the article mentions ApoB reduction of about 50%.

Q: According to the article, what percentage of LDL reduction can be achieved with a combination of Bempedoic acid 180 mg and Ezetimibe 10 mg?

35-40%, The article explicitly states that a combination of Bempedoic acid 180 mg + Ezetimibe 10 mg can reduce LDL by 35-40%. Ezetimibe alone lowers it by 18-25%, and Bempedoic acid alone by 17-23%. The 50-60% reduction is associated with Lipfendra.

Q: Why is the reduction of apolipoprotein B (ApoB) considered particularly important for Indian and South Asian populations?

Because they have a higher prevalence of small, dense LDL particles and dyslipidaemia, The article explains that in people with diabetes and dyslipidaemia, LDL levels may appear normal but the number of small, dense LDL particles (which are more harmful) may be high. South Asians are known to have a higher prevalence of this pattern, making ApoB a more accurate risk marker than LDL alone.

Science & Tech Social IssuesHIGH

Target:UPSC GS-IIIMPSCSSC GATeachingPrelims HighMains MediumStatic GK Link

17 Jul 2026

~2 min

Source: Indian Express

Key Data:LDL reduction up to 60%ApoB reduction ~50%Ezetimibe LDL reduction 18-25%Bempedoic acid LDL reduction 17-23%Combination (Bempedoic acid + Ezetimibe) LDL reduction 35-40%

Bodies:US FDAMerck

Practice MCQs from today's news ▸

~2 min · Quick mode

What This Article Covers

1.Lipfendra (enlicitide) is a first-in-class oral PCSK9 inhibitor approved by the US FDA for LDL cholesterol reduction.

2.It reduces apolipoprotein B (ApoB) by about 50%, a key marker of cardiovascular risk, especially relevant for Indian populations.

3.The drug is intended as an add-on to diet and exercise for adults with high LDL, including those with heterozygous familial hypercholesterolaemia (HeFH).

The Big Picture

Prelims · HighMains · Medium

The US FDA has approved Lipfendra (enlicitide), a once-daily oral PCSK9 inhibitor developed by Merck, that reduces LDL (bad) cholesterol by up to 60%. Unlike statins that reduce cholesterol production, this pill helps the liver clear LDL from the bloodstream by blocking the PCSK9 protein, offering a convenient alternative to expensive injectable PCSK9 inhibitors for high-risk patients.

Exam Lens

Quick Exam Facts From News

Drug NameLipfendra (enlicitide)

Drug ClassPCSK9 inhibitor (oral pill)

DeveloperMerck

Approving AuthorityUS FDA

LDL ReductionUp to 60%

ApoB Reduction~50%

Target ConditionHigh LDL, HeFH

1-Minute Revision

›Drug Name: Lipfendra (enlicitide)
›Drug Class: PCSK9 inhibitor (oral pill)
›Target this Data: Lipfendra (enlicitide) reduces LDL by up to 60% and ApoB by ~50%.
›Target this Nodal Body: US FDA approved the drug; developer is Merck.
›Target this Mechanism: PCSK9 inhibitor – blocks PCSK9 protein to increase LDL receptors on liver.

Mastered this topic? Test your knowledge with a full MCQ quiz.

Practice exam-style questions, track your score, and strengthen your recall.

News Snapshot

💊

Oral PCSK9 Inhibitor Approved

US FDA approves Lipfendra (enlicitide), a once-daily oral pill that lowers LDL cholesterol by up to 60% by blocking the PCSK9 protein.

🫀

Breakthrough for High-Risk Patients

The pill is for patients who need intensive LDL reduction beyond statins, including those with HeFH or who cannot tolerate statins.

📊

ApoB Reduction Key for Indians

Lipfendra also lowers ApoB by 50%, a crucial marker since ApoB levels are higher in Indian populations and reflect artery-clogging particles.

Detailed Analysis & Strategic Depth

Context / Background

Statins have been the first-line therapy for lowering LDL cholesterol by reducing liver production. However, 7-10% of high-risk patients cannot achieve target LDL levels (often <55 mg/dL) with statins and ezetimibe, or they suffer muscle-related side effects. Injectable PCSK9 inhibitors have existed but are expensive and inconvenient. Lipfendra offers the same mechanism in an oral form, potentially improving adherence and access.

Core Analysis & Implications

The approval is significant because it provides an oral alternative to costly injectables, which could reduce healthcare burdens. The reduction in ApoB is particularly important for South Asians, who have a higher prevalence of small, dense LDL particles and dyslipidaemia. The drug is approved as an add-on to diet and exercise for adults with high LDL, including those with HeFH. However, a dedicated cardiovascular outcomes trial is still underway to confirm reduction in heart attacks and strokes.

Future Outlook / Way Forward

While promising, Lipfendra is expected to be expensive initially. Non-statin drugs like ezetimibe (18-25% LDL reduction) and bempedoic acid (17-23%) remain important alternatives before jumping to this new therapy. The drug's impact in India will depend on pricing, regulatory approval by Indian authorities (DCGI), and inclusion in treatment guidelines. The ongoing outcomes trial will be critical for long-term adoption.

Key Facts at a Glance

Drug NameLipfendra (enlicitide)

Drug ClassPCSK9 inhibitor (oral pill)

DeveloperMerck

Approving AuthorityUS FDA

LDL ReductionUp to 60%

ApoB Reduction~50%

Target ConditionHigh LDL, HeFH

You've read the full analysis. Now test your understanding.

Practice exam-style questions based on this article.

Q1Static LinkageEasyUPSC, SSC, Banking

Which regulatory body approved the new oral PCSK9 inhibitor Lipfendra (enlicitide)?

Q2Statement-basedHardUPSC, SSC

Consider the following statements regarding Lipfendra (enlicitide):

1. It is a PCSK9 inhibitor that reduces LDL cholesterol by up to 60%.

2. It works by reducing the liver's production of cholesterol, similar to statins.

3. It also reduces apolipoprotein B (ApoB) levels by about 50%.

Which of the statements given above is/are correct?

Q3Data-centricMediumUPSC, SSC, Banking

According to the article, what percentage of LDL reduction can be achieved with a combination of Bempedoic acid 180 mg and Ezetimibe 10 mg?

Q4Application/ImpactMediumUPSC, SSC, Banking

Why is the reduction of apolipoprotein B (ApoB) considered particularly important for Indian and South Asian populations?

All 25 MCQs ▸

Read original article from Indian Express

You finished this topic

Practice 3 MCQs from this news Next Article

Explore Related Topics

Science & TechView Topic MCQs →Social IssuesView Topic MCQs →

Next Iran Asks Houthis to Prepare Bab el-Mandeb Blockade: 7.4 Million bpd Red Sea Oil Traffic at Risk

Related Current Affairs

Science & Tech Current Affairs

Merck-Moderna mRNA Drug Intismeran Autogene Cuts Melanoma Recurrence in Phase 3 Trial with 1,137 Patients

For the first time, an mRNA-based personalized cancer vaccine (intismeran autogene) developed by Merck and Moderna has proven effective in reducing melanoma recurrence in a large late-stage trial with 1,137 patients. This marks a breakthrough in cancer immunotherapy, demonstrating that mRNA technology, previously successful against COVID-19, can be adapted to fight cancer.

Science & Tech Current Affairs

Merck-Moderna's Personalised mRNA Cancer Vaccine Intismeran Reduces Melanoma Death Risk by 49%

A first-of-its-kind personalised mRNA cancer vaccine (intismeran), developed by Merck and Moderna, combined with Keytruda, has shown a 49% reduction in risk of death from melanoma recurrence and 59% from spread in Phase 3 trials. This marks a breakthrough for cancer vaccines but has limited impact in India due to low melanoma incidence and high cost of immunotherapy.

Science & Tech Current Affairs

CDSCO Approves Qdenga Dengue Vaccine for Ages 4-60; Dr. Reddy's to Distribute in Private Market by 2027

India's first approved dengue vaccine, Qdenga (TAK-003), developed by Takeda, received CDSCO marketing authorisation in July 2026 for ages 4-60. Dr. Reddy's will promote and distribute it in the private market from the first half of 2027, while Takeda retains public market rights. This marks a critical step in addressing India's 11-fold rise in dengue cases over two decades.

Science & Tech Current Affairs

CDSCO Approves Qdenga: India's First Dengue Vaccine to be Distributed by Dr Reddy's from 2027

India’s first approved dengue vaccine Qdenga will enter the private market in 2027 via Dr Reddy’s, after CDSCO approval in July 2026. The vaccine is effective against all four serotypes, requires no pre-vaccination screening, and shows 61.2% efficacy against dengue and 84.1% against hospitalization. This is a landmark step in India's fight against dengue.

Polity Current Affairs

MeitY Summons Meta Global Team Over Algorithmic Bias; Parliamentary Panel to Question

Government summons Meta's global team to clarify algorithmic bias and role in public order after MeitY rejects technical glitch explanation. Parliamentary panel will also question the company. This highlights growing regulatory scrutiny on social media algorithms and their societal impact.

Science & Tech Current Affairs

India Gets First Disease-Modifying Alzheimer's Drug Leqembi After CDSCO Nod

Eisai's Leqembi (lecanemab), India's first disease-modifying therapy for early Alzheimer's, has been launched after CDSCO approval. This marks a shift from symptomatic to disease-modifying treatment, but challenges of early diagnosis, biomarker infrastructure, and affordability remain significant.

Social Issues Current Affairs

NOTTO Reports 20,000+ Transplants in 2025, Launches Portal and Swap Guidelines

NOTTO released 2025 data showing over 20,000 transplants, persistent gender disparity in organ donation (68% female donors vs 78% male recipients), and launched a new digital portal to enhance transparency. New swap transplantation guidelines aim to expand matching beyond single hospitals, but legal recognition under THOTA is still pending.

Science & Tech Current Affairs

IARC Classifies Three WHO Essential Medicines as Group 1 Carcinogens: Hydrochlorothiazide, Voriconazole, Tacrolimus

IARC, the WHO cancer research agency, has classified three widely used drugs—hydrochlorothiazide, voriconazole, and tacrolimus—as Group 1 carcinogens. Despite this, experts stress that patients should not stop treatment as the benefits for hypertension, fungal infections, and organ transplant rejection far outweigh the cancer risk. The drugs are on the WHO Model List of Essential Medicines and are commonly prescribed in India.

Start Today's Quiz(25 Qs)

Take Today's Quiz

25 Qs • 5-7 Mins

FDA Approves Lipfendra (Enlicitide) Oral PCSK9 Inhibitor, Slashes LDL by 60%

Exam Lens

Quick Exam Facts From News

1-Minute Revision

News Snapshot

Oral PCSK9 Inhibitor Approved

Breakthrough for High-Risk Patients

ApoB Reduction Key for Indians

Detailed Analysis & Strategic Depth

Context / Background

Core Analysis & Implications

Future Outlook / Way Forward

Prelims Flashpoints

Key Facts at a Glance